Bioventus (BVS) Net Cash Flow (2020 - 2026)

Bioventus (BVS) has 7 years of Net Cash Flow data on file, last reported at -$14.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 23.04% year-over-year to -$14.8 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (up 1846.62% YoY), and the FY2025 full-year result was $9.3 million, up 29.35% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$14.8 million, down from $8.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $26.3 million in Q2 2023 and bottomed at -$41.4 million in Q3 2022.
• The 5-year median for Net Cash Flow is $47000.0 (2023), against an average of -$2.7 million.
• The widest annual swing landed in 2022, when Net Cash Flow tumbled 583.78%; it then surged 22482.98% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$2.3 million in 2022, then surged by 1014.66% to $21.3 million in 2023, then sank by 97.32% to $571000.0 in 2024, then surged by 1465.85% to $8.9 million in 2025, then sank by 265.35% to -$14.8 million in 2026.
• The last three Net Cash Flow figures came in at -$14.8 million (Q1 2026), $8.9 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.

Peer Comparison